3-(2-Methyl-2H-pyrazol-3-yl)-propionic acid, 95.0%, 250mg

Ethyl (2,4,6-trimethylbenzoyl)phenylphosphinate, 95.0%, 500g

Dipyrazino[2,3-f:2',3'-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile>95.0%(HPLC)(T)1g

METHYL 2-(CHLOROSULFONYL)-3-FLUOROBENZOATE, 95%, 250mg

Guanosine-CPG-Support

2,2'-(Propane-2,2-diylbis(sulfanediyl))diethanamine, 97.0%, 250mg

4-Bromo-5-chloro-N-(2,5-dimethoxybenzyl)-2-fluoro-N-(5-fluorothiazol-2-yl)benzenesulfonamide, 95%, 250mg

5-Butylthio-1,3,4-thiadiazole-2-thiol, 1g

2-Bromo-4-fluoro-1-(methylsulfonyl)benzene, 95.0%, 100mg

3-(Bromoacetyl)pyridine, hydrobromide, 98.0%, 25g

Phase contrast slide with phasing for PLPH 10x and S40x plan phase objectives

mono-Methyl fumarate, 99.0%, 1g

(R)-3-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid, 97%, 500mg